Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Discover numerous legal ways to minimize your taxes and keep more of your hard-earned money. Start optimizing your finances today.
9,076 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
A coalition of states filed antitrust lawsuits to block Paramount Global's planned purchase of Warner Bros. Discovery...
Jim Cramer says he cringes at owning AT&T or Verizon as Bernstein flags Starlink competition risk, signaling a potent...
Gas prices swung in 2026 amid Middle East tensions, lifting refining margins. This article identifies the stocks pois...
Twenty-six Meta employees claim AI-assisted layoff decisions targeted staff on medical or family leave. The suit seek...
Policy clarity clears the path for road ahead build-to-rent projects, lifting investor confidence. Still, the pace of...
Sam Altman raised questions about SpaceX's bold plan for AI data centers in space. This article breaks down the viabi...
Tariff refunds total about $71 billion by June, yet inflationary pressure from the Iran conflict muffles the relief a...
Micron has bounced around the market, but its long-term growth story is coming into sharper focus. This article expla...
ARKK and ARKG are back in the biotech spotlight as Cathie Wood makes new bets after a setback in a key antisense stoc...
Wall Street watches a hypothetical shift as chair kevin warsh just signals a new, discipline-focused approach at the ...
The United States launched strikes on Iranian targets after an attack that killed U.S. troops in Jordan, while Tehran...